NOVO.B.DK

467.45

-2.68%↓

COLO.B.DK

705.6

-3%↓

ZEAL.DK

462.8

-0.22%↓

HLUNB.DK

32.18

-4.74%↓

AMBUB.DK

117.4

-0.89%↓

NOVO.B.DK

467.45

-2.68%↓

COLO.B.DK

705.6

-3%↓

ZEAL.DK

462.8

-0.22%↓

HLUNB.DK

32.18

-4.74%↓

AMBUB.DK

117.4

-0.89%↓

NOVO.B.DK

467.45

-2.68%↓

COLO.B.DK

705.6

-3%↓

ZEAL.DK

462.8

-0.22%↓

HLUNB.DK

32.18

-4.74%↓

AMBUB.DK

117.4

-0.89%↓

NOVO.B.DK

467.45

-2.68%↓

COLO.B.DK

705.6

-3%↓

ZEAL.DK

462.8

-0.22%↓

HLUNB.DK

32.18

-4.74%↓

AMBUB.DK

117.4

-0.89%↓

NOVO.B.DK

467.45

-2.68%↓

COLO.B.DK

705.6

-3%↓

ZEAL.DK

462.8

-0.22%↓

HLUNB.DK

32.18

-4.74%↓

AMBUB.DK

117.4

-0.89%↓

Search

Genmab A-S

Fermé

1,277 -2.59

Résumé

Variation du prix de l'action

24h

Actuel

Min

1266.5

Max

1311

Chiffres clés

By Trading Economics

Revenu

2.1B

3.8B

Ventes

901M

6.4B

P/E

Moyenne du Secteur

11.038

63.778

BPA

60.121

Marge bénéficiaire

59.696

Employés

2,682

EBITDA

-297M

1.8B

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

-1.49% downside

Dividendes

By Dow Jones

Prochains Résultats

1 mai 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-5.2B

85B

Ouverture précédente

1279.59

Clôture précédente

1277

Genmab A-S Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

10 mars 2025, 15:16 UTC

Principaux Mouvements du Marché

Genmab Shares Fall After J&J Drops Blood-Cancer Treatment Option

3 avr. 2024, 13:04 UTC

Acquisitions, Fusions, Rachats

Correction to Genmab Article

3 avr. 2024, 08:08 UTC

Acquisitions, Fusions, Rachats

Genmab Strengthens Oncology Portfolio With $1.8 Billion Acquisition of ProfoundBio

10 déc. 2024, 07:05 UTC

Market Talk

EU Specialty Pharma to See Product Launches But Limited Clinical Data Next Year -- Market Talk

Comparaison

Variation de prix

Genmab A-S prévision

Objectif de Prix

By TipRanks

-1.49% baisse

Prévisions sur 12 Mois

Moyen 2,493.35 DKK  -1.49%

Haut 3,320 DKK

Bas 308.417 DKK

Basé sur 7 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

7 ratings

3

Achat

2

Maintien

2

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Genmab A-S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.